Reed Jobs’s Yosemite Raises $350 Million for Cancer Treatment Innovation
Yosemite secures a second fund to transform cancer into a manageable, non-lethal condition.
1Yosemite Secures New Capital
Reed Jobs has successfully closed a second fund for his venture firm, Yosemite, reaching $350 million. This follows a significant increase from the initial $200 million close reported in January. The firm, which spun out of the Emerson Collective in 2023, focuses exclusively on advancing cancer-related scientific breakthroughs and medical startups.
2Redefining Cancer Treatment Goals
Reed Jobs explicitly rejects the goal of curing cancer, labeling it an unrealistic objective given human biology. Instead, he aims to make cancer a non-lethal condition, drawing a direct parallel to the evolution of AIDS treatment. By managing mortality, he believes the medical industry can achieve a victory over death itself.
3Hybrid Investment and Grant Model
Yosemite utilizes a unique dual-track model that combines traditional venture capital with philanthropic grants. Jobs argues that philanthropy allows for cheaper failure, enabling the firm to test high-risk scientific ideas in university settings. This strategy helps filter out non-viable concepts before committing significant venture capital resources to the development process.
4High-Profile Institutional Support
The fund has attracted a diverse group of limited partners, including major industry players like Amgen and AbbVie. Academic and investment heavyweights such as MIT, Memorial Sloan Kettering, and John Doerr are also backing the initiative. This broad support base underscores the industry's confidence in Yosemite’s long-term approach to oncology innovation.
5Portfolio and Strategic Scope
Yosemite’s previous investments demonstrate a wide-ranging approach to the healthcare ecosystem. The portfolio includes AI-driven drug discovery firm Chai Discovery, cervical cancer screening provider Teal Health, and care navigation startup Sage Care. Jobs emphasizes that no single company can solve cancer, necessitating a consortium of specialized solutions and technologies.
6Scientific Advancements Driving Growth
The biotech sector has experienced a substantial turnaround since Yosemite launched in 2023. Jobs credits this shift to rapid scientific progress, specifically citing advancements in GLP-1s, immunotherapy, and new vaccines targeting pancreatic cancer. These developments have been transformative for the industry, creating new opportunities that were considered impossible just four years ago.
7Operational Philosophy and Timeline
Operating within a traditional venture model, Yosemite seeks venture-scale returns while maintaining a long-term perspective. Jobs acknowledges that the regulatory nature of medicine necessitates a slow pace, but his firm aims to accelerate the discovery phase. He views his work as a lifelong commitment rather than a short-term financial play.
8Legacy and Future Impact
Reed Jobs views his current work as a continuation of his long-term focus, influenced by his personal history with cancer labs. By prioritizing the transition of cancer into a manageable disease, Yosemite positions itself as a critical player in modern oncology. The firm’s success will be measured over decades, not years.
Original article: Fortune — Reed Jobs’s Yosemite Raises $350 Million for Cancer Treatment Innovation